Portfolio company
ORIG3N
United States · £9.9m raised
Raised
£9.9m
Latest stage
Growth
Rounds recorded
1
Backed by
2 investors
Sectors
About
This biotechnology company develops direct-to-consumer genetic testing kits and maintains a biorepository of stem cells to support medical researchers and pharmaceutical firms in drug discovery.
SourceFunding history · 1
Similar companies
Stemnovate
This company develops human cell-based platforms for drug discovery and toxicity testing to support pharmaceutical firms and research institutions.
DropPrint Genomics
This company develops single-cell genomics software and an immune cell database for pharmaceutical researchers and biotechnology firms to improve drug discovery processes.
Oria Bioscience
This company provides isolated biological organelles to pharmaceutical firms and researchers for drug discovery and high-throughput screening applications.
23andMe
The company provides direct-to-consumer genetic testing kits and health reports to individuals for ancestry discovery and health risk assessment.
54gene
This company provides genomic data and research services to pharmaceutical firms and researchers to improve global drug discovery and diagnostic development.
Epigenica
This company develops epigenetic analysis kits and screening tools for researchers in drug discovery, diagnostics, and precision medicine.
Cytochroma
This company manufactures genetically diverse stem cell-derived mini-organs to provide animal-free drug safety and efficacy testing for pharmaceutical and biotechnology organisations.
Bitrobius Genetics
This company develops synthetic gene transfer technology for researchers and pharmaceutical firms to manufacture and deliver cell and gene therapies and vaccines.
